Reverse DCF
What growth does the market imply for AJANTPHARM?
Working backwards from the current price to find the FCF growth assumption baked in.
aggressive
13.9% implied annual FCF growth
The market is pricing in above-average growth. Achievable for a high-quality business but leaves limited margin for error — any slowdown could hurt the price.
Current Price
₹2,823
Historical Growth
3.8%
FCF Yield
2.47%
Price / FCF
40.5x
Plain English
To justify today's price of $2822.70, AJANTPHARM.NS needs to grow its free cash flow at 13.9% per year for the next 10 years. That is 10.2% faster than its historical growth rate of 3.8%. This is optimistic but not impossible for a high-quality business. The stock leaves little room for error — any slowdown could hurt the price.
Adjust Assumptions
Growth Scenarios
What the stock is worth at different growth assumptions
| Scenario | FCF Growth | Implied IV | MoS vs Price |
|---|---|---|---|
| Historical | 3.8% | ₹1,251 | -55.7% |
| Half implied | 7.0% | ₹1,612 | -42.9% |
| GDP rate | 10.0% | ₹2,051 | -27.3% |
| Implied | 13.9% | ₹2,806 | -0.6% |
See full DCF analysis
Bear/base/bull scenarios, sensitivity heatmap, Monte Carlo, and more.
Run Full Analysis →This is an analytical tool, not investment advice. Implied growth is a mathematical inversion of the DCF model and depends on WACC and terminal growth assumptions. YieldIQ is not registered with SEBI as an investment adviser.